Jens Otto L Jorgensen
Overview
Explore the profile of Jens Otto L Jorgensen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
65
Citations
1574
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Jotanovic J, Boldt H, Burton M, Andersen M, Bengtsson D, Bontell T, et al.
Acta Neuropathol
. 2025 Jan;
149(1):4.
PMID: 39747763
No abstract available.
2.
Jotanovic J, Boldt H, Burton M, Andersen M, Bengtsson D, Bontell T, et al.
Acta Neuropathol
. 2024 Nov;
148(1):68.
PMID: 39580368
Aggressive pituitary neuroendocrine tumors (PitNETs)/adenomas are characterized by progressive growth despite surgery and all standard medical therapies and radiotherapy. A subset will metastasize to the brain and/or distant locations and...
3.
Jensen M, Gasbjerg L, Skov-Jeppesen K, Jacobsen J, Poulsen S, Zhou C, et al.
J Clin Endocrinol Metab
. 2024 Aug;
110(3):715-729.
PMID: 39172542
Context: About 30% of patients with active acromegaly experience paradoxically increased growth hormone (GH) secretion during the diagnostic oral glucose tolerance test (OGTT). Endogenous glucose-dependent insulinotropic polypeptide (GIP) is implicated...
4.
Jorgensen J, de Herder W, Martin W, Kolarova T, Marks M, Follin C, et al.
Adv Ther
. 2023 Aug;
40(10):4675-4688.
PMID: 37573277
Introduction: People living with acromegaly and neuroendocrine tumours (NETs) may be treated with injectable somatostatin receptor ligands (SRLs), administered by either a caregiver or as self-injection via a proprietary or...
5.
Bidlingmaier M, Biller B, Clemmons D, Jorgensen J, Nishioka H, Takahashi Y
Front Endocrinol (Lausanne)
. 2023 Mar;
14:1158214.
PMID: 36936137
[This corrects the article DOI: 10.3389/fendo.2022.1040046.].
6.
Falch C, Christiansen Arlien-Soborg M, Dal J, Sundaram A, Michelsen A, Ueland T, et al.
Eur J Endocrinol
. 2023 Mar;
188(3).
PMID: 36895180
Context: Active acromegaly is characterized by lipolysis-induced insulin resistance, which suggests adipose tissue (AT) as a primary driver of metabolic aberrations. Objective: To study the gene expression landscape in AT...
7.
Bidlingmaier M, Biller B, Clemmons D, Jorgensen J, Nishioka H, Takahashi Y
Front Endocrinol (Lausanne)
. 2023 Jan;
13:1040046.
PMID: 36619571
Adult growth hormone deficiency (AGHD) is a rare endocrine disorder characterized by an abnormal body composition, metabolic abnormalities associated with increased cardiovascular diseases, bone loss, and impaired quality of life....
8.
Thomsen H, Olesen J, Aagaard R, Nielsen B, Voss T, Svart M, et al.
Physiol Rep
. 2022 Aug;
10(16):e15399.
PMID: 35986508
Systemic administration of beta-hydroxybutyrate (BHB) decreases whole-body protein oxidation and muscle protein breakdown in humans. We aimed to determine any direct effect of BHB on skeletal muscle protein turnover when...
9.
Laugesen K, Sorensen H, Jorgensen J, Petersen I
Eur J Endocrinol
. 2022 Feb;
186(4):429-440.
PMID: 35104239
Objective: Prenatal exposure to excess cortisol can affect postnatal metabolic health by epigenetic mechanisms. We aimed to investigate if prenatal exposure to pharmacological glucocorticoids increases the risk of overweight/obesity in...
10.
Kuhn E, Weinreich A, Biermasz N, Jorgensen J, Chanson P
Eur J Endocrinol
. 2021 Apr;
185(1):99-108.
PMID: 33914699
Context: Prolactinomas frequently cause amenorrhoea, galactorrhoea and infertility and require dopamine agonist (DA) treatment to normalize prolactin levels and hence, restore ovulation. The vast majority of female patients harbour microprolactinomas...